On the public citation graph

Hematocrit Level and Associated Mortality in Hemodialysis Patients

https://doi.org/10.1681/asn.v103610
0 signed · 559 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.
Claim with ORCID
Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.
See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1007/978-1-4612-4380-9_37openalex-snapshot
Regression Models and Life-Tables
inferredcites →https://doi.org/10.1016/s0272-6386(96)90130-4openalex-snapshot
The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease
inferredcites →https://doi.org/10.1038/ki.1993.158openalex-snapshot
Early dosing practices and effectiveness of recombinant human erythropoietin
inferredcites →https://doi.org/10.1056/nejm199309303291404openalex-snapshot
The Urea Reduction Ratio and Serum Albumin Concentration as Predictors of Mortality in Patients Undergoing Hemodialysis
inferredcites →https://doi.org/10.1093/ndt/10.supp2.62openalex-snapshot
Keynote Lecture: R-HuEPO hyporesponsiveness--who and why?
inferredcites →https://doi.org/10.1093/ndt/12.10.2060openalex-snapshot
National kidney foundation: dialysis outcome quality initiative-development of methodology for clinical practice guidelines
inferredcites →https://doi.org/10.1093/ndt/5.3.232openalex-snapshot
Occult Infection and Resistance of Anaemia to rHuEpo Therapy in Renal Failure
inferredcites →https://doi.org/10.1093/ndt/9.3.270openalex-snapshot
Increased erythropoietin requirements in patients with failed renal transplants returning to a dialysis programme
inferredcites →https://doi.org/10.1111/j.1525-1594.1995.tb02296.xopenalex-snapshot
Normalization of Hematocrit with Recombinant Human Erythropoietin in Chronic Hemodialysis Patients Does Not Fully Improve Their Exercise Tolerance Abilities
inferredcites →https://doi.org/10.1159/000187788openalex-snapshot
Cardiovascular Mortality of Patients with Polycystic Kidney Disease on Dialysis: Is There a Lesson to Learn?
inferredcites →https://doi.org/10.1182/blood.v45.1.55.55openalex-snapshot
The anemia of chronic disorders: studies of marrow regulation and iron metabolism
inferredcites →https://doi.org/10.1681/asn.v471455openalex-snapshot
Effect of recombinant erythropoietin on hospital admissions, readmissions, length of stay, and costs of dialysis patients.
inferredcites →https://doi.org/10.1681/asn.v8121921openalex-snapshot
Anemia in hemodialysis patients
inferredcites →https://doi.org/10.1681/asn.v9112108openalex-snapshot
Dialysis unit and patient characteristics associated with reuse practices and mortality
inferredcites →https://doi.org/10.1681/asn.v94655openalex-snapshot
Neutrophil impairment associated with iron therapy in hemodialysis patients with functional iron deficiency.
inferredcites →https://doi.org/10.1681/asn.v95869openalex-snapshot
EPIBACDIAL
inferredcites →https://doi.org/10.2307/2531529openalex-snapshot
Biases in Prevalent Cohorts
inferredcites →https://doi.org/10.7326/0003-4819-111-12-992openalex-snapshot
Recombinant Human Erythropoietin in Anemic Patients with End-Stage Renal Disease

What points at this work

Incoming claims: where this work appears in other papers’ reference lists and arguments.

inferred← citeshttps://doi.org/10.2139/ssrn.4159341openalex-extracted
Anemia and Hyperuricemia in Patients with Chronic Kidney Disease: A Cross-Sectional Study from Syria
inferred← citeshttps://doi.org/openalex-snapshot
Staphylococcal nasal carriage of health care workers.
inferred← citeshttps://doi.org/10.1001/archinte.163.12.1400openalex-snapshot
Anemia
inferred← citeshttps://doi.org/10.1001/archinte.164.3.262openalex-snapshot
Epoetin Alfa
inferred← citeshttps://doi.org/10.1001/jama.2010.206openalex-snapshot
Comparative Mortality Risk of Anemia Management Practices in Incident Hemodialysis Patients
inferred← citeshttps://doi.org/10.1001/jama.2011.308openalex-snapshot
Serum Levels of Phosphorus, Parathyroid Hormone, and Calcium and Risks of Death and Cardiovascular Disease in Individuals With Chronic Kidney Disease
inferred← citeshttps://doi.org/10.1001/jama.287.10.1262openalex-snapshot
Does Time of Day of Hemodialysis Affect Survival?
inferred← citeshttps://doi.org/10.1001/jama.287.10.1262-bopenalex-snapshot
Does Time of Day of Hemodialysis Affect Survival?
inferred← citeshttps://doi.org/10.1002/14651858.cd013751openalex-snapshot
Hypoxia-inducible factor stabilisers for the anaemia of chronic kidney disease
inferred← citeshttps://doi.org/10.1002/14651858.cd013751.pub2openalex-snapshot
Hypoxia-inducible factor stabilisers for the anaemia of chronic kidney disease
inferred← citeshttps://doi.org/10.1002/9780470994931.ch1openalex-snapshot
Dialysis and the Chronic Renal Failure Patient
inferred← citeshttps://doi.org/10.1002/9781119187547.ch23openalex-snapshot
Identifying Biomarker Profiles Through the Epidemiologic Analysis of Big Health Care Data – Implications for Clinical Management and Clinical Trial Design
inferred← citeshttps://doi.org/10.1002/9781119484288.ch22openalex-snapshot
Anaemia in older people
inferred← citeshttps://doi.org/10.1002/9781444319583.ch20openalex-snapshot
Anemia and Cardiovascular Disease
inferred← citeshttps://doi.org/10.1002/ajh.20140openalex-snapshot
Prevalence and characteristics of anemia in the elderly: Cross‐sectional study of three urban Korean population samples
inferred← citeshttps://doi.org/10.1002/ajh.21805openalex-snapshot
Biosimilar epoetins and other “follow‐on” biologics: Update on the European experiences
inferred← citeshttps://doi.org/10.1002/ajh.23255openalex-snapshot
Hemoglobin level and survival in hemodialysis patients with polycystic kidney disease and the role of administered erythropoietin
inferred← citeshttps://doi.org/10.1002/dat.20006openalex-snapshot
Controversies in renal anemia management
inferred← citeshttps://doi.org/10.1002/dat.20297openalex-snapshot
Pro‐Hepcidin Levels in Peritoneal Dialysis and Hemodialysis Patients
inferred← citeshttps://doi.org/10.1002/jbmr.4272openalex-snapshot
The HIF-PHI BAY 85-3934 (Molidustat) Improves Anemia and Is Associated With Reduced Levels of Circulating FGF23 in a CKD Mouse Model
inferred← citeshttps://doi.org/10.1002/jbmr.4297openalex-snapshot
Erythropoietin treatment and the risk of hip fractures in hemodialysis patients
inferred← citeshttps://doi.org/10.1002/jcph.1713openalex-snapshot
A Physiological Approach to Pharmacokinetics in Chronic Kidney Disease
inferred← citeshttps://doi.org/10.1002/pds.1799openalex-snapshot
Greater Epoetin alfa (EPO) doses and short‐term mortality risk among hemodialysis patients with hemoglobin levels less than 11 g/dL
inferred← citeshttps://doi.org/10.1002/sim.3392openalex-snapshot
Joint analysis of multi‐level repeated measures data and survival: an application to the end stage renal disease (ESRD) data
inferred← citeshttps://doi.org/10.1007/978-1-4020-2275-3_39openalex-snapshot
Management of anemia in patients with chronic kidney disease
inferred← citeshttps://doi.org/10.1007/978-1-4471-5547-8_50openalex-snapshot
Anaemia Management in Chronic Kidney Disease
inferred← citeshttps://doi.org/10.1007/978-1-4614-3694-2_2openalex-snapshot
Anemia and Cardiovascular Risk in the Kidney Disease Patients: What Is the Best Way to Achieve and What Is the Desired Hemoglobin?
inferred← citeshttps://doi.org/10.1007/978-1-59745-032-4_13openalex-snapshot
Anemia Management
inferred← citeshttps://doi.org/10.1007/978-3-030-37655-0_4openalex-snapshot
Chronic Kidney Disease and End Stage Renal Disease
inferred← citeshttps://doi.org/10.1007/978-3-030-62087-5_45openalex-snapshot
Management of Anemia in Peritoneal Dialysis Patients
inferred← citeshttps://doi.org/10.1007/978-3-030-83082-3_13openalex-snapshot
Anemia in Chronic Kidney Disease
inferred← citeshttps://doi.org/10.1007/978-3-031-42045-0_15openalex-snapshot
Anemia and Disorders of Hemostasis in Chronic Kidney Disease
inferred← citeshttps://doi.org/10.1007/978-3-319-56042-7_26openalex-snapshot
Cardiomyopathy in the Potential Kidney Transplant Candidate
inferred← citeshttps://doi.org/10.1007/978-3-319-90760-4_45-1openalex-snapshot
Management of Anemia in Peritoneal Dialysis Patients
inferred← citeshttps://doi.org/10.1007/978-3-7643-8698-6_13openalex-snapshot
Use of erythropoietic stimulating agents in the setting of renal disease
inferred← citeshttps://doi.org/10.1007/978-94-015-9998-6_3openalex-snapshot
Has the best route of administration for epoetin been established?
inferred← citeshttps://doi.org/10.1007/978-94-015-9998-6_9openalex-snapshot
Are uremic inhibitors of erythropoiesis clinically relevant?
inferred← citeshttps://doi.org/10.1007/978-981-97-7636-8_13openalex-snapshot
Treatment of Renal Anemia in a Maintenance Hemodialysis Patient with Viral Hepatitis B Infection
inferred← citeshttps://doi.org/10.1007/s00216-007-1521-7openalex-snapshot
Reduction of the interferences of biochemicals and hematocrit ratio on the determination of whole blood glucose using multiple screen-printed carbon electrode test strips
inferred← citeshttps://doi.org/10.1007/s00431-022-04650-1openalex-snapshot
Comparison of darbepoetin alpha and recombinant human erythropoietin for treatment of anemia in pediatric chronic kidney disease: a non-inferiority trial from India
inferred← citeshttps://doi.org/10.1007/s00467-003-1214-1openalex-snapshot
Morbidity and mortality in children with anemia at initiation of dialysis
inferred← citeshttps://doi.org/10.1007/s00467-006-0071-0openalex-snapshot
Darbepoetin alfa for the treatment of anemia in pediatric patients with chronic kidney disease
inferred← citeshttps://doi.org/10.1007/s00467-007-0737-2openalex-snapshot
Slowing chronic kidney disease progression: results of prospective clinical trials in adults
inferred← citeshttps://doi.org/10.1007/s00467-019-04359-8openalex-snapshot
Effects of changes in adult erythropoietin dosing guidelines on erythropoietin dosing practices, anemia, and blood transfusion in children on hemodialysis: findings from North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS)
inferred← citeshttps://doi.org/10.1007/s00467-023-05977-zopenalex-snapshot
Real-world evidence on the dosing and safety of C.E.R.A. in pediatric dialysis patients: findings from the International Pediatric Dialysis Network registries
inferred← citeshttps://doi.org/10.1007/s00592-004-0134-2openalex-snapshot
New strategies in anaemia management: ACORD (Anaemia CORrection in Diabetes) trial
inferred← citeshttps://doi.org/10.1007/s005920200003openalex-snapshot
Cardiac disease in diabetic patients with renal disease
inferred← citeshttps://doi.org/10.1007/s10157-012-0659-6openalex-snapshot
The impact of hyporesponsiveness to erythropoietin-stimulating agents on time-dependent mortality risk among CKD stage 5D patients: a single-center cohort study
inferred← citeshttps://doi.org/10.1007/s10157-022-02225-wopenalex-snapshot
Clinical parameters among patients in Japan with anemia and non-dialysis-dependent chronic kidney disease with and without diabetes mellitus who received roxadustat
inferred← citeshttps://doi.org/10.1007/s10286-004-0207-xopenalex-snapshot
QT?interval parameters in end?stage renal disease
inferred← citeshttps://doi.org/10.1007/s10557-007-6075-6openalex-snapshot
Correction of Anemia with Erythropoietin in Chronic Kidney Disease (stage 3 or 4): Effects on Cardiac Performance
inferred← citeshttps://doi.org/10.1007/s10557-010-6239-7openalex-snapshot
Cardiovascular Risks of Anemia Correction with Erythrocyte Stimulating Agents: Should Blood Viscosity Be Monitored for Risk Assessment?
inferred← citeshttps://doi.org/10.1007/s10557-022-07321-3openalex-snapshot
Role of Erythropoiesis-Stimulating Agents in Cardiovascular Protection in CKD Patients: Reappraisal of Their Impact and Mechanisms
inferred← citeshttps://doi.org/10.1007/s10741-008-9083-0openalex-snapshot
Erythropoietin: physiology and molecular mechanisms
inferred← citeshttps://doi.org/10.1007/s11136-007-9176-6openalex-snapshot
Relation between level or change of hemoglobin and generic and disease-specific quality of life measures in hemodialysis
inferred← citeshttps://doi.org/10.1007/s11255-006-0035-0openalex-snapshot
Iron deficiency in patients with chronic kidney disease: potential role for intravenous iron therapy independent of erythropoietin
inferred← citeshttps://doi.org/10.1007/s11255-011-0028-5openalex-snapshot
Iron overdose: a contributor to adverse outcomes in randomized trials of anemia correction in CKD
inferred← citeshttps://doi.org/10.1007/s11812-006-0008-3openalex-snapshot
Anämien
inferred← citeshttps://doi.org/10.1007/s11906-016-0629-6openalex-snapshot
Hypoxia-Inducible Factor Stabilizers: a New Avenue for Reducing BP While Helping Hemoglobin?
inferred← citeshttps://doi.org/10.1007/s12011-021-02888-8openalex-snapshot
Association Between the Blood Copper-Zinc (Cu/Zn) Ratio and Anemia in Patients Undergoing Maintenance Hemodialysis
inferred← citeshttps://doi.org/10.1007/s12288-019-01170-1openalex-snapshot
Updates on Novel Erythropoiesis-Stimulating Agents: Clinical and Molecular Approach
inferred← citeshttps://doi.org/10.1007/s13340-024-00693-xopenalex-snapshot
Changes in serum levels of liver-related parameters, uric acid, and hemoglobin in patients with type 2 diabetes mellitus under treatment with tofogliflozin—a post-hoc analysis of the UTOPIA study
inferred← citeshttps://doi.org/10.1007/s42600-024-00381-4openalex-snapshot
Effect of red blood cell concentration on the blood flow in patient-specific aneurysms
inferred← citeshttps://doi.org/10.1016/b978-0-12-373870-7.00005-3openalex-snapshot
Erythropoietin, Anemia and Kidney Disease
inferred← citeshttps://doi.org/10.1016/b978-0-323-52978-5.00009-4openalex-snapshot
Anemia in Chronic Kidney Disease
inferred← citeshttps://doi.org/10.1016/b978-012193155-1/50042-8openalex-snapshot
Nutrition and Renal Disease
inferred← citeshttps://doi.org/10.1016/b978-1-4160-3105-5.50051-7openalex-snapshot
10.1016/b978-1-4160-3105-5.50051-7
inferred← citeshttps://doi.org/10.1016/b978-1-4160-3105-5.50057-8openalex-snapshot
10.1016/b978-1-4160-3105-5.50057-8
inferred← citeshttps://doi.org/10.1016/b978-1-4160-4197-9.50063-6openalex-snapshot
Use of Erythropoietic-Stimulating Agents in Hemodialysis Patients
inferred← citeshttps://doi.org/10.1016/b978-1-4160-6164-9.00048-2openalex-snapshot
Kidney Disease
inferred← citeshttps://doi.org/10.1016/b978-1-4377-0987-2.00007-8openalex-snapshot
Anemia in Chronic Kidney Disease
inferred← citeshttps://doi.org/10.1016/b978-141605484-9.50069-1openalex-snapshot
Iron and Erythropoietin-Related Therapies
inferred← citeshttps://doi.org/10.1016/b978-2-294-07878-1.50034-1openalex-snapshot
BIBLIOGRAPHIE GÉNÉRALE
inferred← citeshttps://doi.org/10.1016/b978-3-437-23900-7.50015-8openalex-snapshot
Chronische Niereninsuffizienz
inferred← citeshttps://doi.org/10.1016/j.ajkd.2003.06.001openalex-snapshot
Hospitalization during advancing chronic kidney disease
inferred← citeshttps://doi.org/10.1016/j.amjcard.2012.05.008openalex-snapshot
Comparison of Chronic Kidney Disease and Risk for Presenting With Painless Versus Nonpainless Acute Myocardial Infarction
inferred← citeshttps://doi.org/10.1016/j.amjcard.2014.02.019openalex-snapshot
Impact of Continuous Deterioration of Kidney Function 6 to 8 Months After Percutaneous Coronary Intervention for Acute Coronary Syndrome
inferred← citeshttps://doi.org/10.1016/j.annepidem.2008.09.008openalex-snapshot
Exercise and Limitations in Physical Activity Levels among New Dialysis Patients in the United States: An Epidemiologic Study
inferred← citeshttps://doi.org/10.1016/j.array.2026.100837openalex-snapshot
A Manifold Learning Model for Adjusting Anemia Treatment in Chronic Kidney Disease
inferred← citeshttps://doi.org/10.1016/j.bios.2012.02.010openalex-snapshot
Improvement of electrical blood hematocrit measurements under various plasma conditions using a novel hematocrit estimation parameter
inferred← citeshttps://doi.org/10.1016/j.cardfail.2004.06.435openalex-snapshot
Anemia and New-Onset Congestive Heart Failure in the General Medicare Population
inferred← citeshttps://doi.org/10.1016/j.ccl.2005.03.002openalex-snapshot
Pathophysiology of Cardiovascular Disease and Renal Failure
inferred← citeshttps://doi.org/10.1016/j.cger.2008.03.003openalex-snapshot
Anemia in Diabetic Patients
inferred← citeshttps://doi.org/10.1016/j.ecoenv.2022.113714openalex-snapshot
Exposure to melamine and its derivatives in Chinese adults: The cumulative risk assessment and the effect on routine blood parameters
inferred← citeshttps://doi.org/10.1016/j.ekir.2026.106383openalex-snapshot
Mortality and Practice Patterns in the MEXHEMO Hemodialysis Cohort
inferred← citeshttps://doi.org/10.1016/j.hfc.2010.02.001openalex-snapshot
Anemia in Chronic Kidney Disease: New Advances
inferred← citeshttps://doi.org/10.1016/j.ijengsci.2023.103901openalex-snapshot
Analysis and prediction of hematocrit in microvascular networks
inferred← citeshttps://doi.org/10.1016/j.ijid.2020.09.010openalex-snapshot
High prevalence of parvovirus B19 infection in patients with chronic kidney disease under hemodialysis: A multicenter study
inferred← citeshttps://doi.org/10.1016/j.jacc.2004.06.058openalex-snapshot
The renal patient with coronary artery disease
inferred← citeshttps://doi.org/10.1016/j.jacc.2009.02.047openalex-snapshot
The Scope of Coronary Heart Disease in Patients With Chronic Kidney Disease
inferred← citeshttps://doi.org/10.1016/j.jacc.2011.07.010openalex-snapshot
Chronic Kidney Disease and Risk for Presenting With Acute Myocardial Infarction Versus Stable Exertional Angina in Adults With Coronary Heart Disease
inferred← citeshttps://doi.org/10.1016/j.jclinepi.2004.05.002openalex-snapshot
Hematocrit was not validated as a surrogate end point for survival among epoetin-treated hemodialysis patients
inferred← citeshttps://doi.org/10.1016/j.jtemb.2022.126947openalex-snapshot
Association between the blood manganese (Mn) and hemoglobin in patients undergoing maintenance hemodialysis
inferred← citeshttps://doi.org/10.1016/j.jtv.2018.11.002openalex-snapshot
Oral mucosa pressure ulcers in intensive care unit patients: A preliminary observational study of incidence and risk factors
inferred← citeshttps://doi.org/10.1016/j.jvs.2017.05.108openalex-snapshot
A preoperative risk score for transfusion in infrarenal endovascular aneurysm repair to avoid type and cross
inferred← citeshttps://doi.org/10.1016/j.jvs.2017.05.114openalex-snapshot
Preoperative anemia is associated with mortality after carotid endarterectomy in symptomatic patients
inferred← citeshttps://doi.org/10.1016/j.kint.2016.09.013openalex-snapshot
Hemoglobin of 12 g/dl and above is not associated with increased cardiovascular morbidity in children on hemodialysis
inferred← citeshttps://doi.org/10.1016/j.krcp.2014.11.003openalex-snapshot
Optimal hemoglobin level for anemia treatment in a cohort of hemodialysis patients
inferred← citeshttps://doi.org/10.1016/j.krcp.2015.10.006openalex-snapshot
Overhydration measured by bioimpedance analysis and the survival of patients on maintenance hemodialysis: a single-center study
inferred← citeshttps://doi.org/10.1016/j.lfs.2016.01.050openalex-snapshot
Effect of normovolemic hematocrit changes on blood pressure and flow
inferred← citeshttps://doi.org/10.1016/j.nephro.2008.04.009openalex-snapshot
Incidence et prise en charge de l’anémie en transplantation rénale : une étude observationnelle française
inferred← citeshttps://doi.org/10.1016/j.nephro.2008.09.002openalex-snapshot
La prise en charge de l’anémie du patient hémodialysé en France s’améliore-t-elle ? Résultats de l’étude DiaNE
inferred← citeshttps://doi.org/10.1016/j.nephro.2011.03.011openalex-snapshot
Faisabilité de la stratégie d’administration de la darbepoetin alfa tous les 15 jours : expérience 2005–2007 d’un centre de dialyse
inferred← citeshttps://doi.org/10.1016/j.semnephrol.2004.06.012openalex-snapshot
Epidemiology and prevention of cardiovascular complication in chronic kidney disease patients
inferred← citeshttps://doi.org/10.1016/j.semnephrol.2004.09.011openalex-snapshot
Dialysis outcomes as a measure of adequacy of dialysis
inferred← citeshttps://doi.org/10.1016/j.semnephrol.2005.05.008openalex-snapshot
Anemia and Heart Failure in Chronic Kidney Disease
inferred← citeshttps://doi.org/10.1016/j.semnephrol.2006.05.005openalex-snapshot
Anemia and the Heart in Chronic Kidney Disease
inferred← citeshttps://doi.org/10.1016/j.transproceed.2004.07.038openalex-snapshot
The new rHuEPO alpha (epotin) in the management of anemia of end-stage renal disease in patients on mantainence hemodialysis
inferred← citeshttps://doi.org/10.1016/j.transproceed.2010.07.092openalex-snapshot
Prevalence and Predictive Factors of Anemia after Renal Transplantation: A Moroccan Report
inferred← citeshttps://doi.org/10.1016/j.transproceed.2012.05.084openalex-snapshot
Chronic Renal Failure Complications and Management in Kidney Transplanted and Nontransplanted Patients
inferred← citeshttps://doi.org/10.1016/j.vhri.2014.01.001openalex-snapshot
Cost-Utility Analysis of Erythropoietin for Anemia Treatment in Thai End-Stage Renal Disease Patients with Hemodialysis
inferred← citeshttps://doi.org/10.1016/j.xkme.2019.06.009openalex-snapshot
Long-term Safety of Epoetin Alfa-epbx for the Treatment of Anemia in ESKD: Pooled Analyses of Randomized and Open-label Studies
inferred← citeshttps://doi.org/10.1016/s0140-6736(03)12195-2openalex-snapshot
Transfusion medicine: looking to the future
inferred← citeshttps://doi.org/10.1016/s0140-6736(07)60194-9openalex-snapshot
Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis
inferred← citeshttps://doi.org/10.1016/s0167-5273(02)00273-5openalex-snapshot
The prevalence of anemia in chronic heart failure
inferred← citeshttps://doi.org/10.1016/s0272-6386(00)70062-xopenalex-snapshot
Go to bed and get a good night's sleep: You need your rest!
inferred← citeshttps://doi.org/10.1016/s0272-6386(00)70333-7openalex-snapshot
Impact of disease severity and hematocrit level on reuse-associated mortality
inferred← citeshttps://doi.org/10.1016/s0272-6386(01)70008-xopenalex-snapshot
IV. NKF-K/DOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease: Update 2000
inferred← citeshttps://doi.org/10.1016/s0272-6386(01)80078-0openalex-snapshot
Treatment of anemia of chronic kidney disease
inferred← citeshttps://doi.org/10.1016/s0272-6386(03)00188-4openalex-snapshot
Chronic kidney disease: issues and establishing programs and clinics for improved patient outcomes
inferred← citeshttps://doi.org/10.1016/s0272-6386(04)01086-8openalex-snapshot
Epoetin requirements predict mortality in hemodialysis patients
inferred← citeshttps://doi.org/10.1016/s0272-6386(04)01102-3openalex-snapshot
Anemia management for hemodialysis patients: Kidney Disease Outcomes Quality Initiative (K/DOQI) guidelines and Dialysis Outcomes and Practice Patterns Study (DOPPS) findings
inferred← citeshttps://doi.org/10.1016/s0272-6386(05)90000-0openalex-snapshot
Subcutaneous erythropoietin results in lower dose and equivalent hematocrit levels among adult hemodialysis patients: Results from the 1998 End-Stage Renal Disease Core Indicators Project
inferred← citeshttps://doi.org/10.1016/s0272-6386(99)70012-0openalex-snapshot
Mortality risks of peritoneal dialysis and hemodialysis
inferred← citeshttps://doi.org/10.1016/s0735-1097(00)00613-6openalex-snapshot
The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations
inferred← citeshttps://doi.org/10.1016/s0735-1097(01)01248-7openalex-snapshot
The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study
inferred← citeshttps://doi.org/10.1016/s0889-8529(01)00006-8openalex-snapshot
Endocrine abnormalities in chronic renal failure
inferred← citeshttps://doi.org/10.1016/s1096-6374(03)00063-7openalex-snapshot
End-stage renal disease: endocrine aspects of treatment
inferred← citeshttps://doi.org/10.1016/s1130-6343(08)76279-2openalex-snapshot
Calidad de la farmacoterapia y seguridad de los pacientes en hemodiálisis tratados con estimulantes eritropoyéticos
inferred← citeshttps://doi.org/10.1016/s1262-3636(07)80056-5openalex-snapshot
Diabetic nephropathy in the elderly
inferred← citeshttps://doi.org/10.1016/s1441-2772(23)01647-2openalex-snapshot
Should the replacement of acute blood loss with non-red blood cell solutions in the elderly be called resuscitation or embalming?
inferred← citeshttps://doi.org/10.1016/s1561-5413(08)60001-0openalex-snapshot
Management of Anemia in Dialysis Patients—The Whats and Hows
inferred← citeshttps://doi.org/10.1016/s1762-0945(06)40516-7openalex-snapshot
Anémie de l'insuffisance rénale chronique
inferred← citeshttps://doi.org/10.1016/s1769-7255(05)80005-7openalex-snapshot
Argumentaire
inferred← citeshttps://doi.org/10.1016/s1769-7255(09)75175-2openalex-snapshot
Taux d’hémoglobine et risque cardiovasculaire
inferred← citeshttps://doi.org/10.1016/s2173-5085(08)70053-4openalex-snapshot
Pharmacotherapy quality and patient safety in haemodialysis patients treated with erythropoiesis-stimulating agents
inferred← citeshttps://doi.org/10.1017/9781108942751.040openalex-snapshot
Anemia and Other Hematological Problems
inferred← citeshttps://doi.org/10.1017/cbo9781107294967.037openalex-snapshot
Anemia and other hematological problems in the elderly
inferred← citeshttps://doi.org/10.1021/acsbiomaterials.9b01590openalex-snapshot
Estimating Tumor Vascular Permeability of Nanoparticles Using an Accessible Diffusive Flux Model
inferred← citeshttps://doi.org/10.1034/j.1600-6143.2001.0010s2001.xopenalex-snapshot
The Evaluation of the Renal Transplant Candidates: Clinical Practice Guidelines
inferred← citeshttps://doi.org/10.1038/ki.2008.286openalex-snapshot
Negative trials in nephrology: what can we learn?
inferred← citeshttps://doi.org/10.1038/ki.2008.295openalex-snapshot
Secondary analysis of the CHOIR trial epoetin-α dose and achieved hemoglobin outcomes
inferred← citeshttps://doi.org/10.1038/ki.2008.523openalex-snapshot
Factors that condition the response to erythropoietin in patients on hemodialysis and their relation to mortality
inferred← citeshttps://doi.org/10.1038/ki.2008.524openalex-snapshot
Maintenance of target hemoglobin level in stable hemodialysis patients constitutes a theoretical task: a historical prospective study
inferred← citeshttps://doi.org/10.1038/ki.2009.231openalex-snapshot
Posttransplant anemia: the role of sirolimus
inferred← citeshttps://doi.org/10.1038/ki.2009.415openalex-snapshot
A secondary analysis of the CHOIR trial shows that comorbid conditions differentially affect outcomes during anemia treatment
inferred← citeshttps://doi.org/10.1038/ki.2009.496openalex-snapshot
Anemia trials: lessons for clinicians, politicians, and third-party payers
inferred← citeshttps://doi.org/10.1038/ki.2010.209openalex-snapshot
Pretransplant cardiovascular evaluation and posttransplant cardiovascular risk
inferred← citeshttps://doi.org/10.1038/ki.2011.81openalex-snapshot
Journal Club
inferred← citeshttps://doi.org/10.1038/ncpneph0655openalex-snapshot
Mechanisms of Disease: erythropoietin resistance in patients with both heart and kidney failure
inferred← citeshttps://doi.org/10.1038/ncpneph0847openalex-snapshot
Anemia and anemia correction: surrogate markers or causes of morbidity in chronic kidney disease?
inferred← citeshttps://doi.org/10.1038/nrneph.2011.169openalex-snapshot
ESA responsiveness and outcomes in patients on hemodialysis
inferred← citeshttps://doi.org/10.1038/nrneph.2013.21openalex-snapshot
Anaemia management and mortality risk in chronic kidney disease
inferred← citeshttps://doi.org/10.1038/s41371-017-0023-0openalex-snapshot
Left ventricular hypertrophy and cognitive function: a systematic review
inferred← citeshttps://doi.org/10.1038/s41598-021-94165-wopenalex-snapshot
Low hemoglobin levels and an increased risk of psoriasis in patients with chronic kidney disease
inferred← citeshttps://doi.org/10.1038/s41598-024-80709-3openalex-snapshot
Associations between serum potassium variability and mortality in patients undergoing maintenance hemodialysis: a retrospective study
inferred← citeshttps://doi.org/10.1038/sj.ki.5000430openalex-snapshot
Response to time to consider the role of epoetin
inferred← citeshttps://doi.org/10.1038/sj.ki.5001971openalex-snapshot
Can higher hemoglobin prolongs life for patients with kidney disease?
inferred← citeshttps://doi.org/10.1038/sj.ki.5001995openalex-snapshot
Introduction: Improving outcomes in chronic kidney disease
inferred← citeshttps://doi.org/10.1038/sj.ki.5002688openalex-snapshot
The effect of epoetin dose on hematocrit
inferred← citeshttps://doi.org/10.1039/c3lc00020fopenalex-snapshot
An electrochemical Lab-on-a-CD system for parallel whole blood analysis
inferred← citeshttps://doi.org/10.1039/c5an01251aopenalex-snapshot
Determination of hematocrit by voltage-induced hemolysis on a disposable electrochemical sensing strip
inferred← citeshttps://doi.org/10.1046/j.1365-2257.2001.00352.xopenalex-snapshot
The pathological consequences of anaemia
inferred← citeshttps://doi.org/10.1046/j.1440-1797.2000.00006.xopenalex-snapshot
Target haemoglobin levels for the treatment of the anaemia of chronic renal failure
inferred← citeshttps://doi.org/10.1046/j.1523-1755.2000.00289.xopenalex-snapshot
Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy
inferred← citeshttps://doi.org/10.1046/j.1523-1755.2000.00878.xopenalex-snapshot
Anemia management of adult hemodialysis patients in the U.S.: Results from the 1997 ESRD Core Indicators Project
inferred← citeshttps://doi.org/10.1046/j.1523-1755.2001.00002.xopenalex-snapshot
Trends in anemia at initiation of dialysis in the United States
inferred← citeshttps://doi.org/10.1046/j.1523-1755.2001.00060.xopenalex-snapshot
Clinical performance measures: The changing status of peritoneal dialysis11Note: The Centers for Medicare and Medicaid Services (CMS), formerly the Health Care Financing Administration (HCFA) ESRD Core Indicators Study, supplied the data described in this report. The interpretation and reporting…
inferred← citeshttps://doi.org/10.1046/j.1523-1755.2001.00806.xopenalex-snapshot
Cardiac arrest and sudden death in dialysis units
inferred← citeshttps://doi.org/10.1046/j.1523-1755.2002.00144.xopenalex-snapshot
Hyperhomocysteinemia predicts cardiovascular outcomes in hemodialysis patients
inferred← citeshttps://doi.org/10.1046/j.1523-1755.2002.00314.xopenalex-snapshot
Sodium ferric gluconate complex in hemodialysis patients: Adverse reactions compared to placebo and iron dextran
inferred← citeshttps://doi.org/10.1046/j.1523-1755.2002.00373.xopenalex-snapshot
Opportunities to improve the care of patients with kidney transplant failure
inferred← citeshttps://doi.org/10.1046/j.1523-1755.2002.00432.xopenalex-snapshot
Health care utilization among patients with chronic kidney disease
inferred← citeshttps://doi.org/10.1046/j.1523-1755.2002.00474.xopenalex-snapshot
Novel erythropoiesis-stimulating protein in the management of the anemia of chronic renal failure
inferred← citeshttps://doi.org/10.1046/j.1523-1755.2003.00079.xopenalex-snapshot
The cost-effectiveness of maintaining higher hemoglobin targets with erythropoietin in hemodialysis patients
inferred← citeshttps://doi.org/10.1046/j.1523-1755.2003.00229.xopenalex-snapshot
Hemoglobin variability in epoetin-treated hemodialysis patients
inferred← citeshttps://doi.org/10.1046/j.1523-1755.2003.00937.xopenalex-snapshot
The effects of higher hemoglobin levels on mortality and hospitalization in hemodialysis patients
inferred← citeshttps://doi.org/10.1046/j.1523-1755.61.s80.3.xopenalex-snapshot
Strategies to decrease cardiovascular mortality in patients with end-stage renal disease
inferred← citeshttps://doi.org/10.1046/j.1523-1755.61.s80.8.xopenalex-snapshot
What should the optimal target hemoglobin be?11This article is dedicated to the memory of Fernando Valderrábano, who, over the last decade, was involved in the study of renal anemia with the goal of achieving optimal care and improved quality of life for all patients with CKD.
inferred← citeshttps://doi.org/10.1046/j.1523-1755.61.s80.9.xopenalex-snapshot
Influence of target hemoglobin in dialysis patients on morbidity and mortality
inferred← citeshttps://doi.org/10.1046/j.1523-1755.63.s85.25.xopenalex-snapshot
Traditional and emerging cardiovascular risk factors in end-stage renal disease
inferred← citeshttps://doi.org/10.1046/j.1523-1755.64.s87.21.xopenalex-snapshot
Prospective trials on anemia of chronic disease: The Trial to Reduce Cardiovascular Events with Aranesp® Therapy (TREAT)
inferred← citeshttps://doi.org/10.1046/j.1523-1755.64.s87.4.xopenalex-snapshot
Anemia of chronic disease: Past, present, and future
inferred← citeshttps://doi.org/10.1046/j.1525-139x.1999.90217.xopenalex-snapshot
Clinical Factors Associated with Changing Hematocrit Levels in Hemodialysis Patients
inferred← citeshttps://doi.org/10.1046/j.1525-139x.2000.00104.xopenalex-snapshot
The Comparative Safety of Intravenous Iron Dextran, Iron Saccharate, and Sodium Ferric Gluconate
inferred← citeshttps://doi.org/10.1046/j.1525-139x.2002.00011.xopenalex-snapshot
Editorial Focus: Dialysis Quality and Outcomes: Quality Outcomes and Obstacles to Their Achievement in End‐Stage Renal Disease
inferred← citeshttps://doi.org/10.1046/j.1525-139x.2002.00055.xopenalex-snapshot
Study Designs and Their Potential Influence on Conclusions
inferred← citeshttps://doi.org/10.1046/j.1525-139x.2002.0006d.xopenalex-snapshot
How Can the Cardiac Death Rate be Reduced in Dialysis Patients?
inferred← citeshttps://doi.org/10.1046/j.1525-139x.2003.16022.xopenalex-snapshot
THE CLINICAL EPIDEMIOLOGY OF CARDIOVASCULAR DISEASES IN CHRONIC KIDNEY DISEASE: Introduction
inferred← citeshttps://doi.org/10.1046/j.1525-139x.2003.160271.xopenalex-snapshot
THE CLINICAL EPIDEMIOLOGY OF CARDIOVASCULAR DISEASES IN CHRONIC KIDNEY DISEASE: Clinical Epidemiology of Cardiac Disease in Dialysis Patients: Left Ventricular Hypertrophy, Ischemic Heart Disease, and Cardiac Failure
inferred← citeshttps://doi.org/10.1046/j.1525-139x.2003.16029.xopenalex-snapshot
THE CLINICAL EPIDEMIOLOGY OF CARDIOVASCULAR DISEASES IN CHRONIC KIDNEY DISEASE: Hemodynamic Cardiovascular Risk Factors in Chronic Kidney Disease: What are the Effects of Intervention?
inferred← citeshttps://doi.org/10.1046/j.1525-1594.2002.06878.xopenalex-snapshot
Does Treatment Modality Have an Impact on Anemia in Patients with Chronic Renal Failure? Effect of Low‐ and High‐Flux Biocompatible Dialysis
inferred← citeshttps://doi.org/10.1046/j.1600-6143.2004.00604.xopenalex-snapshot
Percentage of Hypochromic Red Blood Cells is an Independent Risk Factor for Mortality in Kidney Transplant Recipients
inferred← citeshttps://doi.org/10.1053/ajkd.1999.v34.aajkd0344b0005openalex-snapshot
National perspective on iron therapy as a clinical performance measure for maintenance hemodialysis patients
inferred← citeshttps://doi.org/10.1053/ajkd.2000.19830openalex-snapshot
Adequacy of dialysis and differences in hematocrit among dialysis facilities
inferred← citeshttps://doi.org/10.1053/ajkd.2000.19927openalex-snapshot
Defining a renal anemia management period
inferred← citeshttps://doi.org/10.1053/ajkd.2000.19930openalex-snapshot
Anemia management in patients with chronic renal insufficiency
inferred← citeshttps://doi.org/10.1053/ajkd.2000.8972openalex-snapshot
Hematocrit levels and associated Medicare expenditures
inferred← citeshttps://doi.org/10.1053/ajkd.2001.26824openalex-snapshot
Quality of life in end-stage renal disease patients
inferred← citeshttps://doi.org/10.1053/ajkd.2001.26842openalex-snapshot
Gender modulates responsiveness to recombinant erythropoietin
showing the first 200 of 541
Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.